Ph 3 Trial of Disitamab Vedotin in 1L HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma meets Primary Endpoints of PFS and OS
“The strongly positive results of DV in combination with toripalimab as a first-line treatment for advanced urothelial carcinoma are encouraging. DV combined with toripalimab significantly improved PFS and OS, irrespective of cisplatin eligibility or HER2 expression level, which proves the success of HER2-ADC plus immunotherapy and represents a major breakthrough in the treatment of urothelial carcinoma worldwide. It is expected that the excellent performance of disitamab vedotin in subsequent studies will provide better decision-making basis for clinicians, bring more benefits to patients, and reshape the global treatment landscape of urothelial carcinoma with the Chinese regimen,”said Dr. Jun Guo, principal investigator of the study and professor at Peking University Cancer Hospital.
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000